{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:02:23Z","timestamp":1793707343485,"version":"4.6.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejphar.2020.173114","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T19:27:25Z","timestamp":1586892445000},"page":"173114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["Statins and PCSK9 inhibitors: A new lipid-lowering therapy"],"prefix":"10.1016","volume":"878","author":[{"given":"Enrique","family":"Gallego-Colon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aner","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Yosefy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejphar.2020.173114_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"17","key":"10.1016\/j.ejphar.2020.173114_bib2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Accord Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173114_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"9753","key":"10.1016\/j.ejphar.2020.173114_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9493","key":"10.1016\/j.ejphar.2020.173114_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173114_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"issue":"25","key":"10.1016\/j.ejphar.2020.173114_bib8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"18","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12915-018-0624-2","article-title":"In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model","volume":"17","author":"Carreras","year":"2019","journal-title":"BMC Biol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173114_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173114_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-018-0319-9","article-title":"Recombinant antibody production in CHO and NS0 cells: differences and similarities","volume":"32","author":"Dhara","year":"2018","journal-title":"BioDrugs"},{"issue":"15","key":"10.1016\/j.ejphar.2020.173114_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1161\/CIRCULATIONAHA.118.036069","article-title":"Alirocumab's price reduction","volume":"138","author":"Dhruva","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173114_bib13","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173114_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin\u2013kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"issue":"32","key":"10.1016\/j.ejphar.2020.173114_bib15","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248417724868","article-title":"Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables","volume":"23","author":"Filippatos","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173114_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2018.09.011","article-title":"Incretin drugs as modulators of atherosclerosis","volume":"278","author":"Gallego-Colon","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2020.173114_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jcph.840","article-title":"Impact of target-me- diated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase sub- tilisin\/kexin type 9 (PCSK9)","volume":"57","author":"Gibbs","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"10106","key":"10.1016\/j.ejphar.2020.173114_bib19","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejphar.2020.173114_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","article-title":"Pharmacotherapies for lipid modification: beyond the statins","volume":"10","author":"Gotto","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"issue":"24","key":"10.1016\/j.ejphar.2020.173114_bib21","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.ejphar.2020.173114_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIR.0000000000000312","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system","volume":"133","author":"Halperin","year":"2016","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ejphar.2020.173114_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008953","article-title":"PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review","volume":"7","author":"Handelsman","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173114_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"12","key":"10.1016\/j.ejphar.2020.173114_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173114_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173114_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.ejphar.2020.173114_bib28","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173114_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ejphar.2020.173114_bib31","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2020.173114_bib32","first-page":"28","volume":"vol. 41","author":"Manniello","year":"2016"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib33","first-page":"13","article-title":"LDL cholesterol: the lower the better","volume":"96","author":"Martin","year":"2012","journal-title":"Med. Clin."},{"issue":"25","key":"10.1016\/j.ejphar.2020.173114_bib34","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable Atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173114_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004816","article-title":"Statins for preventing cardiovascular disease","author":"Moore","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173114_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.15277\/bjd.2018.180","article-title":"Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes","volume":"18","author":"Naeem","year":"2018","journal-title":"Br. J. Diabetes"},{"issue":"25","key":"10.1016\/j.ejphar.2020.173114_bib37","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (Ncep)","year":"2002","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ejphar.2020.173114_bib38","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance","volume":"315","author":"Nissen","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.ejphar.2020.173114_bib39","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173114_bib40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2337\/diacare.28.3.595","article-title":"Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia","volume":"28","author":"Parris","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173114_bib41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","article-title":"Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention","volume":"59","author":"Perreault","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"15","key":"10.1016\/j.ejphar.2020.173114_bib42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173114_bib43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2020.173114_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","article-title":"Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events","volume":"178","author":"Ridker","year":"2016","journal-title":"Am. Heart J."},{"issue":"16","key":"10.1016\/j.ejphar.2020.173114_bib45","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173114_bib46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association","volume":"13","author":"Robinson","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"20","key":"10.1016\/j.ejphar.2020.173114_bib47","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"15","author":"Roth","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"18","key":"10.1016\/j.ejphar.2020.173114_bib49","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ejphar.2020.173114_bib50","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173114_bib51","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.clinthera.2015.09.001","article-title":"Nonstatin therapies for management of dyslipidemia: a review","volume":"37","author":"Sando","year":"2015","journal-title":"Clin. Therapeut."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173114_bib52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am. Heart J."},{"issue":"22","key":"10.1016\/j.ejphar.2020.173114_bib53","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173114_bib54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","article-title":"New developments in proprotein convertase subtilisin\u2013kexin 9\u02bcs biology and clinical implications","volume":"27","author":"Seidah","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173114_bib55","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173114_bib56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-200104000-00008","article-title":"Very-low-density lipoprotein assembly and secretion","volume":"12","author":"Shelness","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173114_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002497","article-title":"Overcoming challenges with statin therapy","volume":"5","author":"Spence","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"9836","key":"10.1016\/j.ejphar.2020.173114_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejphar.2020.173114_bib59","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173114_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol."},{"issue":"25 Suppl. 2","key":"10.1016\/j.ejphar.2020.173114_bib61","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in Adults","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173114_bib62","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173114_bib63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The Hps2-Thrive Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ejphar.2020.173114_bib64","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/ijms20235936","article-title":"Heterozygous ldlr-deficient hamster as a model to evaluate the efficacy of PCSK9 antibody in hyperlipidemia and atherosclerosis","volume":"20","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920302065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920302065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:36:20Z","timestamp":1757975780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920302065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":64,"alternative-id":["S0014299920302065"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173114","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and PCSK9 inhibitors: A new lipid-lowering therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173114"}}